PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Surg Res. Author manuscript; available in PMC May 15, 2012.
Published in final edited form as:
PMCID: PMC3077465
NIHMSID: NIHMS257769
SURGICAL SEPSIS AND ORGAN CROSSTALK: THE ROLE OF THE KIDNEY
Laura E. White, MD,1* Rahul Chaudhary, MD,1* Laura J. Moore, MD,1 Frederick A. Moore, MD,1 and Heitham T. Hassoun, MD1,2
1 Department of Surgery, The Methodist Hospital and Research Institute, Houston TX
2 The Methodist DeBakey Heart and Vascular Center, Houston TX
Correspondence to: Heitham T. Hassoun, M.D. Associate Professor of Cardiovascular Surgery The Methodist Hospital Physician Organization 6550 Fannin Street, SM 1401 Houston, TX 77030 Telephone: 713/441-6201 Fax: 713/709-3058 ; hhassoun/at/tmhs.org
*Contributed equally to the authorship of this manuscript
Acute kidney injury (AKI) is a common complication of hospitalized patients, and clinical outcomes remain poor despite advances in renal replacement therapy. The accepted pathophysiology of AKI in the setting of sepsis has evolved from one of simple decreased renal blood flow to one that involves a more complex interaction of intra-glomerular microcirculatory vasodilation combined with the local release of inflammatory mediators and apoptosis. Evidence from pre-clinical AKI models suggests that crosstalk occurs between kidneys and other organ systems via soluble and cellular inflammatory mediators, and that this involves both the innate and adaptive immune systems. These interactions are reflected by genomic changes and abnormal rates of cellular apoptosis in distant organs including the lungs, heart, gut, liver, and central nervous system. The purpose of this article is to review the influence of AKI, particularly sepsis-associated AKI, on inter-organ crosstalk in the context of systemic inflammation and multiple organ failure (MOF).
Keywords: Acute kidney injury, sepsis, inflammation, apoptosis, immune response
Acute Kidney Injury (AKI) is a common and often catastrophic complication amongst hospitalized patients. It affects 3-7% of patients admitted to the hospital and approximately 25-30% of patients in the Intensive Care Unit (ICU) [1]. Mortality rates for ICU patients with AKI have a reported range from 30-70% even with advances in renal replacement therapy, and AKI is an independent risk factor for mortality even after adjustment for demographics, severity of illness and other patient factors [2, 3]. AKI has been summarized by two consensus definitions: 1) The Risk-Injury-Failure-Loss-Endstage renal disease (RIFLE) classification, and 2) The Acute Kidney Injury Network (AKIN) criteria. The RIFLE classification uses serum creatinine or glomerular filtration rate (GFR) and urine flow per body weight over time to stratify renal injury by severity, with “risk” as the least severe category and “failure” as the most severe category. The AKIN classification modified the RIFLE criteria in 2007 to exclude GFR and classify AKI into stages 1-3, with stage 3 representing the requirement for renal replacement therapy [4].
Despite the advancement in renal replacement therapy, the mortality rates associated with AKI have remained unchanged over the past 2 decades [3]. Both clinical and translational laboratory studies have demonstrated very complex mechanisms of interactions between the injured kidney and distant organs such as the lung, heart, liver, gut, brain and hematological system. Recent studies on AKI-associated distant organ dysfunction have highlighted the importance of both the innate and adaptive immune response, activation of pro-inflammatory cascades and an alteration in transcriptional events during ischemic AKI. For example, cell adhesion molecule and cytokine-chemokine expression, apoptosis dysregulation and leukocyte trafficking to distant organs all occur during ischemic AKI. The goal of this manuscript is to review emerging concepts regarding the clinical significance of sepsis-associated AKI, the altered immune response that follows, and the mechanisms by which AKI contributes to distant organ injury. For a complete list of abbreviations used in this manuscript, please see Table 1.
Table 1
Table 1
Abbreviations
Sepsis is a well-established risk factor for AKI, and mortality rates in patients with both AKI and sepsis are much greater than the mortality rate in patients with either AKI or sepsis alone, particularly in the setting of MOF [5]. Thus, the combination of sepsis and AKI poses a particularly serious problem and the concept that sepsis-associated AKI may have a distinct pathophysiology from other etiologies of AKI is supported not only by experimental data and evidence from small clinical studies, but also by epidemiological data showing ‘dose response’ trends in incidence rates and outcomes for septic AKI by severity of either sepsis or AKI [5-11] (Figure 1).
Figure 1
Figure 1
Surgical Sepsis and Multiple Organ Failure- The Role of the Kidney
While the etiology of AKI in critically ill patients is multi-factorial, sepsis has consistently been a leading contributing factor for AKI in the ICU setting [12-16]. The Centers for Disease Control has listed sepsis as the 10th leading cause of death, and annual costs due to this disease exceed $17 billion [17]. The National Surgical Quality Improvement Project (NSQIP) dataset from the American College of Surgeons defines sepsis as the presence of systemic inflammatory response syndrome (SIRS) with a source of infection, as documented by positive blood cultures or purulence from any site thought to be causative [18]. Severe sepsis is defined as sepsis associated with organ dysfunction, hypoperfusion abnormality, or sepsis-induced hypotension by the American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) Consensus Conference Guidelines [19]. Severe sepsis is not separately identified by NSQIP data but is included in the definition of septic shock, sepsis with organ and/or circulatory dysfunction (Table 2) [20, 21].
Table 2
Table 2
Sepsis and Related Definitions
Surgical sepsis, defined as sepsis requiring surgical intervention for source control or sepsis within 14 days of a surgical procedure, occurs more frequently than other post-operative complications such as pulmonary embolism and myocardial infarction [18, 21]. The published incidence rate of surgical sepsis is 3 cases per 1,000 patients and it carries a high mortality rate ranging from 26-50% [16]. The prevalence of AKI in patients with severe sepsis or septic shock has been reported as high as 43% [14]. While the epidemiology of surgical sepsis-associated AKI is largely unknown, prior studies describing sepsis-associated AKI have consistently concluded that it contributes to nearly two-fold higher mortality than either non-septic AKI or sepsis alone [12-16]. This is likely due to the fact that AKI rarely occurs in isolation and is associated with distant organ dysfunction in the context of multiple organ failure (MOF).
Surgical sepsis is considered different from medical sepsis for several reasons. First, surgical trauma and anesthetic agents used during surgery alter host local and systemic immune function. Surgical trauma systemically activates macrophages, neutrophils, natural killer cells and endothelial cells of the innate immune response which then in turn synthesize mediators including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). The adaptive immune response is also activated, mediated by pro-inflammatory type-1 helper cells (Th1) and anti-inflammatory type-2 helper cells (Th2) [22]. Additionally, in contrast to the medical ICU population, patients who have surgical sepsis often require source control in the form of urgent surgical intervention. The timing of source control must be coordinated with resuscitation efforts, but has the potential to dramatically reverse the cycle of septic shock. Patients with surgical sepsis who are at highest risk for AKI are those whose clinical instability requires aggressive volume resuscitation and hemodynamic support with broad spectrum antimicrobial coverage prior to operative intervention. The appropriate timing of source control is unknown, however expert consensus opinion recommends this should be completed within six hours in order to break the cycle of persistent septic shock [23].
Traditional concepts of sepsis-associated AKI
The pathophysiology of sepsis-associated AKI is complex and multi-factorial. Traditionally, AKI in sepsis and septic shock was thought to result from renal ischemia secondary to vasoconstriction and inadequate renal blood flow (RBF). Some of the major mechanisms that have also been linked either directly or indirectly to sepsis-associated AKI include: 1) alterations in hemodynamics with subsequent renal vasoconstriction leading to ischemia and tissue hypoxia, 2) hyperglycemia causing functional alterations in leukocytes and macrophages leading to inflammation, and 3) activation of the coagulation and fibrinolytic cascades leading to disseminated intravascular coagulation (DIC) and micro-vascular thrombosis [11, 24].
Changing paradigm in the pathophysiology of sepsis-associated AKI
Our understanding of sepsis-associated AKI pathophysiology is shifting from renal vasoconstriction, ischemia and acute tubular necrosis to that of heterogeneous vasodilation, hyperemia and acute tubular apoptosis. The concept of renal vasoconstriction and kidney ischemia as a key pathogenic factor is certainly valid for all low-flow states (i.e. cardiogenic or hemorrhagic shock). However, during hyperdynamic states (i.e. sepsis and other acute systemic inflammatory conditions), the hemodynamic alterations within the kidney appear to be heterogeneous, with reduced perfusion to microvascular beds despite increased total RBF [25]. Human data on renal hemodynamics in sepsis is limited, but a recent systematic review of the available experimental evidence showed that in all three human studies and in 30% of animal studies, RBF remained unchanged or even increased. Cardiac output (CO) was found to be the only statistically significant predictor of RBF. Furthermore, the majority of studies reporting a reduction in renal blood flow were derived mostly from hypodynamic models characterized by a reduced cardiac output. In multiple experimental models in which hyperdynamic sepsis was produced, RBF increased proportionately to CO. Therefore, it is likely that the AKI associated with sepsis occurs in a setting of normal or even raised RBF resulting in a hyperemic kidney [25-27].
The loss of GFR can now be explained by the differences in the glomerular capillary pressure created by the afferent and efferent renal vessels. In this condition, there is disproportionally increased renal vasodilation in the efferent blood vessels as compared to the afferent vessels. This causes a reduction in glomerular capillary pressure, in turn, leading to a reduced GFR and causing oliguria and reduced solute clearance. This hypothesis was confirmed with animal models of hyperdynamic sepsis in which angiotensin II, a vasoconstrictor hormone which causes a preferential increase in efferent arteriole resistance, was administered by continuous infusion. The animals which received the infusion demonstrated a restored arterial blood pressure and a significantly increased urine output and creatinine clearance compared to placebo [28]. Thus, it seems that sepsis-associated AKI does not result from ischemia secondary to decreased overall renal blood flow, but instead from derangements inside the glomerulus leading to decreased GFR.
Though sepsis-associated AKI may result from heterogeneous hypoperfusion as opposed to global renal hypoperfusion, similar injury patterns are demonstrated in experimental models of both sepsis and IRI induced AKI. In addition to intra-glomerular vascular changes, non-hemodynamic effects of sepsis-associated AKI are locally mediated by the release of inflammatory cytokines, particularly TNF-α, with subsequent tubular cell apoptosis [29]. Studies have shown that endotoxin stimulates the release of TNF-α from glomerular mesangial cells [30]. Additional work has demonstrated attenuation of TNF-α mediated acute renal failure in both TNF receptor-neutralized and in TNF receptor knockout mice [31, 32]. Cellular apoptosis, which is an energy-requiring and genetically-directed process, has been demonstrated to occur alongside necrosis in experimental models of both ischemia-reperfusion and septic acute kidney injury. Apoptosis was elicited in cultured kidney proximal tubular and glomerular cells by both TNF-α and lipopolysaccharide (LPS) [33, 34]. Caspases, enzymes responsible for carrying out apoptosis, are inhibited in animal models of both LPS-induced sepsis and kidney IRI, and in this setting, mice treated with caspase inhibitors are protected from both sepsis and IRI associated AKI [35, 36].
Hyperglycemia and DIC commonly occur in patients with sepsis and MOF, and therapies including intensive insulin therapy (IIT) and activated protein C (APC) decrease both the onset of sepsis-associated AKI and mortality [11, 37]. The benefits of IIT are most profound in patients with surgical sepsis, and a number of physiologic mechanisms of renal protection have been proposed [38]. Despite a lack of influence on hemodynamics, IIT improves the lipid profile in patients with sepsis and MOF, and attenuation of both ischemic and endotoxemic AKI by high density lipoprotein has been demonstrated in experimental models [39-41]. AKI and hyperglycemia are also associated with an increase in expression of inducible nitric oxide synthase (iNOS), endothelial activation of ICAM-1, upregulation of pro-inflammatory cytokines (TNFα, IL-6), release of oxidative stress mediators and infiltration of inflammatory cells, which lead to renal tubular injury [38, 42, 43]. Additionally, APC has anti-inflammatory, antithrombotic and profibrinolytic properties and reduces mortality in severe sepsis [37]. In a model of polymicrobial sepsis induced by cecal ligation and puncture, APC administration decreased the expression of inflammatory cytokines, the incidence of apoptosis and the presence of acute tubular necrosis [44].
In summary, AKI associated with sepsis can be characterized by a vasomotor nephropathy which includes disturbances in renal microcirculation, activation of pro-inflammatory mediators, and activation of renal cell apoptosis, thus resulting in kidney failure and imbalances in body water and electrolyte homeostasis. Due to the difficulties associated with measuring these effects simultaneously and the complexity of the condition, further studies will be needed to elucidate the detailed mechanisms of sepsis-associated AKI and the pathway for recovery of kidney function after injury.
The incidence of AKI continues to increase and is associated with a changing spectrum of illnesses, significant co-morbid and extra-renal complications, and unsatisfactory preventive or treatment strategies [45-47]. Despite advances in treatment such as renal replacement therapy, mortality rates associated with AKI have not changed significantly since the 1950’s [2, 3]. This is likely due to the fact that AKI rarely occurs in isolation and is usually a component of inter-organ crosstalk and MOF. It is apparent that much of the increased risk of death is derived from extra-renal complications related to remote organ damage and dysfunction. More recently, animal studies have shown a direct effect of AKI on distant organs such as the lung, brain, liver and the gut [48-53]. These animal studies include models of IRI and sepsis, namely LPS endotoxin-induced sepsis, due to its reproducibility in creating distant organ failure including AKI [54].
Kidney- Lung interactions during AKI
Currently, the kidney and lung represent the two most commonly involved organs in MOF [55]. Acute lung injury (ALI) is defined by the American-European Consensus Conference on Acute Respiratory Distress Syndrome (ARDS) as a PaO2/FiO2 ratio of less than 300 and chest radiograph findings of acute bilateral infiltrates in the absence of elevated cardiac filling pressures [56]. Acute hypoxia is a frequent presenting symptom of postoperative sepsis, and a decreased PaO2/FiO2 ratio results from increased pulmonary shunting in response to acidosis and carbon monoxide retention. ALI accounts for a significant component of the mortality associated with AKI even in the absence of volume overload contributed by renal failure [57-59]. The mortality of combined AKI and ALI is extremely high and may approach 80% [60]. Therefore, defining the mechanisms of kidney-lung crosstalk in the critically ill is necessary for reducing overall mortality associated with AKI.
Mechanisms of Kidney-Lung Crosstalk
The mechanisms of AKI-associated lung injury remain incompletely understood. Several studies have demonstrated the involvement of pro-inflammatory and pro-apoptotic factors such as leukocyte trafficking, cytokines/chemokines, activation of caspases, oxidative stress, and uremic toxins. AKI and ALI act as a self propagating cycle (Figure 2). AKI leads to lung injury and inflammation and in turn, ALI, with its attendant hypoxemia and hypercapnia worsened by mechanical ventilation-associated high positive-end expiratory pressure (PEEP), causes a decline in renal hemodynamics and function. Experimental evidence has demonstrated that lung injury in the setting of AKI is featured by marked pulmonary microvascular permeability, erythrocyte sludging in lung capillaries, interstitial edema, focal alveolar hemorrhage and inflammatory cell infiltration [49, 52, 59]. Kidney ischemia-reperfusion injury (IRI) has been shown not only to cause an increase in pulmonary vascular permeability, but it also results in down-regulation of the pulmonary epithelial salt and water transporters (ENaC, Na, K-ATPase and aquaporins) in the rat lung, all of which contribute to decreased alveolar fluid clearance [49, 59, 61].
Figure 2
Figure 2
Vicious cycle of AKI and ALI
Role of inflammation, cytokines and chemokines
The upregulation of pro-inflammatory genes and inflammatory cytokines are important mediators connecting the effects of AKI on distant organs [62]. Recent studies by Hassoun and colleagues investigated the lung structural, functional and genomic response during kidney IRI or bilateral nephrectomy (BNx) [52, 63]. A comprehensive genomic map and analysis of inflammation-associated transcriptional changes in local and remote organs during ischemic AKI identified markedly similar transcriptomic changes occurring concomitantly in both the kidney and lung during AKI, including significant changes in the expression of 109 prominent proinflammatory genes including Cd14, serum amyloid A 3 (Saa3), lipocalin 2, CXCL-2 and the IL-1 receptor (IL-1r2) [63]. Of note, the demonstrated changes in the lung following ischemic AKI were distinguishable from those caused by uremia alone and involved early and persistent activation of proinflammatory and proapoptotic pathways [52].
Cytokines/chemokines have a key role in the initiation as well as progression of both AKI and ALI. Interleukin-6 (IL-6), inteleukin-10 (IL-10), and Saa3 are increased in the lung during AKI [59, 64]. Klein et al. demonstrated that IL-6 is elevated after both ischemic AKI and BNx in mice and in the serum of patients with AKI, and furthermore predicts mortality [61]. The same investigators also discovered that IL-6-deficiency reduced lung neutrophil infiltration, myeloperoxidase activity, expression of the chemokines KC (CXCL-1) and MIP-2 (macrophage inflammatory protein-2) and capillary leak during AKI in mice. Another recent study has demonstrated cytokine-mediated pulmonary injury during AKI, including increased IL-6, IL-1, IL-12 (p40), granulocyte macrophage colony-stimulating factor (GM-CSF), whereby anti-inflammatory IL-10 inhibits both production and action of numerous pro-inflammatory cytokines and reduced lung injury during AKI [53, 61]. Clearly, the mechanisms by which inflammation might initiate and affect AKI-induced ALI are complex and only partially understood, but may be influenced by regulation of cytokines and chemokines.
Lung apoptosis
There is increasing evidence that pulmonary cell apoptosis may play an important role in the pathophysiology of AKI induced ALI [65]. Both enhanced pulmonary endothelial and epithelial cell apoptosis and delayed leukocyte apoptosis have been associated with ALI [66-68]. Investigations of vascular permeability have highlighted the importance of the balance between complex tethering forces involved in cell-to-cell and cell-to-extracellular matrix interactions. These studies have also shown that endothelial apoptosis leads to the disruption of these complex interactions and a potential for loss of endothelial barrier function [69]. Recent laboratory data demonstrated that kidney IRI in rats induces pulmonary endothelial apoptosis and lung injury, and these effects were abrogated by the caspase inhibitor z-VAD-fmk, suggesting a direct role of caspase dependent apoptosis in ischemic AKI induced lung injury [70].
Role of innate and adaptive immunity
Kidney ischemia-reperfusion injury activates both the innate and adaptive immune responses [71]. The innate immune response includes neutrophils, macrophages and possibly natural killer cells. The adaptive immune system is also activated after kidney IRI via CD4 + T cells, particularly of the Th1 phenotype [71]. Pathogenesis of post-ischemic injury is thought to be mediated by interferon-γ (INF-γ) produced by CD4+ T cells [72]. Additionally, the inactivation of IL-16, a chemoattractant strongly expressed on renal tubules during IRI, resulted in less IRI-induced CD4+ lymphocyte trafficking and subsequent kidney injury and dysfunction [73]. T lymphocyte trafficking occurs as early as one hour after kidney IRI and persists for up to 6 weeks post injury [74, 75]. In fact, these T cells may recognize antigens released during kidney IRI and subsequently target the kidney in an autoimmune response, leading to long term progression of renal dysfunction. This mechanism was demonstrated in a murine adoptive transfer model in which naïve mice received T cells from mice who were 6 weeks post-kidney IRI and subsequently developed increased albuminuria [74].
Leukocytes play a fundamental role in the development of ALI/ARDS and several recent studies have documented lung leukocyte activation and trafficking during experimental AKI. In rat models of both bilateral kidney IRI and bilateral nephrectomy, studies have shown early and sustained lung neutrophil sequestration [53, 76]. While neutrophils are the key mediators in several extra-pulmonary models of ALI such as sepsis and mesenteric IRI, their importance in AKI-associated lung injury is less clear, and in fact, uremic neutrophils have been shown to attenuate ALI in mice [51].
Macrophage and lymphocyte infiltration and/or proliferation are other potential mediators of the distant organ effects of AKI. Macrophage activation inhibitor CNI-1493 has been shown to attenuate lung microvascular leak following bilateral kidney IRI in rats [49]. In addition, unilateral kidney ischemia has resulted in increased macrophages in both the contralateral kidney as well as the cardiac interstitium [77]. Lie et al have recently reported on the infiltration of activated CD3+ CD8+ cytotoxic T lymphocytes into mouse lungs during kidney IRI and their potential role in mediating lung apoptosis in this setting [78].
Kidney interactions with other distant organs
Acute kidney injury interacts with and affects many other major organ-systems including the heart, brain and central nervous system, the hematologic system, the liver and gut [79]. Though the exact pathophysiology of these interactions are unclear, the general mechanisms by which AKI induces distant organ effects remain fairly universal and include inflammation, activation of both soluble and cellular factors, as well as hemodynamic and neurohumoral alterations which lead to cellular apoptosis and organ damage (Figure 3).
Figure 3
Figure 3
Acute Kidney Injury and its effects on major organ-systems in the body
Kidney-Heart Interactions
While cardiovascular collapse is one of the most common causes for death in the setting of AKI, the mechanisms involved are incompletely understood [80]. It has been demonstrated by Kelly et al. that during kidney IRI in rats there is left ventricular (LV) dilatation, increased left ventricular end diastolic and end systolic diameter, increased relaxation time, and decreased fractional shortening [81]. It has also been shown that cardiac ischemia, in a setting of AKI, causes a sustained ventricular fibrillation of longer duration than cardiac ischemia without AKI [82]. Conversely, some studies have shown that ischemic preconditioning of the kidney can induce distant organ protection in certain circumstances, protecting the myocardium against irreversible damage produced by prolonged coronary artery occlusion under hypothermic conditions [47].
Cardiac myocyte apoptosis and neutrophil infiltration are two of the most important contributors to the pathophysiology of myocardial infarction during AKI and transgenic models have demonstrated that even apoptosis alone can lead to lethal heart failure [5, 31, 77, 78, 83]. During AKI, there is an increased amount of both cardiac and systemic TNF-alpha and IL-1 along with increased expression of ICAM-1 mRNA, which results in myocyte apoptosis and neutrophil infiltration of the heart [48, 84]. Decreased renal ischemia time attenuates cardiac apoptosis and IL-1 and ICAM-1 levels, as does administration of anti-TNF-α antibodies [48].
Kidney-Brain Interactions
Effects of AKI on brain and nervous system include early clinical signs such as clumsiness, fatigue, impaired concentration and apathy which may later progress to delirium, confusion and coma. Interestingly, dialysis improves, but fails to fully correct, central nervous system manifestations of renal failure in both the acute and chronic setting [85]. Much of the symptoms of encephalopathy are attributed to uremic toxins, however both soluble and cellular inflammatory mediators, similar to those seen in kidney-lung and kidney-heart interactions, have also been implicated.
It has been demonstrated that AKI causes an increase in the levels of soluble mediators such as KC, G-CSF and GFAP in the cerebral cortex and hippocampus of the brain, which may function to recruit neutrophils to sites of neuronal damage. This increased KC and G-CSF in the brain potentially represent increased neuronal production of these pro-inflammatory factors or an accumulation of these proteins through an altered blood-brain barrier (increased micro-vascular permeability) arising from a systemic or renal source. AKI also causes a cell-mediated inflammatory response in the brain such as seen with activated microglial cells (brain macrophages) [86].
Kidney-Liver Interactions
Liver injury often correlates with severity of kidney injury. Ischemic AKI has been shown to induce oxidative stress and promote inflammation, apoptosis and tissue damage in hepatocytes. Hepatic stellate cells (HSCs) are known to regulate leukocyte trafficking and activation by secreting chemokines such as interleukin-8 (IL-8) [87]. Crosstalk between CD40-expressing HSCs and immune effector cells likely occurs through activating nuclear factor κβ (NF-κβ) and c-Jun N-terminal kinase to up-regulate chemokine secretion [88]. These HSCs are LPS-inducible, and LPS endotoxemia causes hepatic injury by enhancing neutrophil transmigration out of the hepatic sinusoid and into the liver parenchyma [89].
During ischemic and non-ischemic AKI, oxidative stress causes hepatic malondialdehyde, an index of lipid peroxidation, to increase while total glutathione (a antioxidant) decreases [90]. Oxidative stress occurs as a component of the surgical stress response, particularly after IRI, sepsis, kidney and liver failure [91-93]. Oxidative stress also plays an important role in sepsis-associated AKI. In an animal model of sepsis induced by cecal ligation and puncture, the administration of antioxidants ethyl pyruvate and methyl-2-acetamidoacrylate (M2AA) significantly reduced mortality, improved the pro- and anti-inflammatory cytokine response, and attenuated liver and kidney injury [94, 95]. Kidney-liver crosstalk during AKI therefore likely occurs by a complex combination of soluble inflammatory mediators and cellular immunity.
Kidney-Gut Interactions
In the past, investigators and clinicians have labeled the gut as the “motor” of MOF due to its ability to amplify the systemic SIRS response in the setting of shock and gut hypoperfusion [96-98]. Mechanisms by which this crosstalk occurs include increased intestinal epithelial permeability, interactions between host and bacterial pathogens, and propagation of toxins to distant organs via the lymphatic system [97, 99-101]. These mechanisms could potentially play a role in the converse direction of interactions between the kidney and the gut during AKI.
Our understanding of how AKI influences gut physiology is limited, however the gut has been shown to mitigate some adverse effects of AKI, particularly in the handling of excess potassium. Clinical studies have long demonstrated the increased secretion of potassium by the colon and rectum [102, 103]. Recent literature has linked channel-inducing factor (CHIF), a potassium channel regulator found in both the kidney and the colon, to ischemic IRI. In animals subjected to kidney IRI, CHIF was upregulated in the colon while a renal secretory potassium channel, ROMK1, was downregulated in the kidney, possibly explaining why hyperkalemia does not universally occur in AKI [50, 104]. Aldosterone secreted from the kidney is associated with the upregulation of CHIF in the gut and may serve a role in kidney-gut crosstalk, however much potential for research exists in elucidating the mechanisms of AKI induced gut injury [50].
CONCLUSION
AKI is a common complication in hospitalized patients, and mortality rates of AKI in conjunction with sepsis and MOF are unacceptably high. Our understanding of the pathophysiology of sepsis-associated AKI continues to evolve, as does our understanding of the mechanisms by which AKI induces distant organ failure. Further investigation of AKI-induced distant organ effects may lead to potential therapeutic targets and a future reduction in patient mortality.
Acknowledgments
Supported by: NIH K08HL089181
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
1. Barry M, Brenner FCR. Brenner and Rector’sThe Kidney. Saunders, An Imprint of Elsevier; 2007.
2. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. Jama. 1996;275:1489–1494. [PubMed]
3. Metnitz PG, Krenn CG, Steltzer H, Lang T, Ploder J, Lenz K, Le Gall JR, Druml W. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med. 2002;30:2051–2058. [PubMed]
4. Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN--time for reappraisal. Crit Care. 2009;13:211. [PMC free article] [PubMed]
5. Edelstein CL, S. R. Disease of the Kidney and Urinary Tract. Lippincott Williams and Wilkins; Philadelphia: 2001.
6. Brenner M, Schaer GL, Mallory DL, Suffredini AF, Parrillo JE. Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter. Chest. 1990;98:170–179. [PubMed]
7. Langenberg C, Wan L, Bagshaw SM, Egi M, May CN, Bellomo R. Urinary biochemistry in experimental septic acute renal failure. Nephrol Dial Transplant. 2006;21:3389–3397. [PubMed]
8. Langenberg C, Wan L, Egi M, May CN, Bellomo R. Renal blood flow in experimental septic acute renal failure. Kidney Int. 2006;69:1996–2002. [PubMed]
9. Lucas CE, Rector FE, Werner M, Rosenberg IK. Altered renal homeostasis with acute sepsis. Clinical significance. Arch Surg. 1973;106:444–449. [PubMed]
10. Rector F, Goyal SC, Rosenberg IK, Lucas CE. Renal hyperemia in association with clinical sepsis. Surg Forum. 1972;23:51–53. [PubMed]
11. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359–1367. [PubMed]
12. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C, Kellum JA. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol. 2007;2:431–439. [PubMed]
13. Lopes JA, Jorge S, Resina C, Santos C, Pereira A, Neves J, Antunes F, Prata MM. Acute renal failure in patients with sepsis. Crit Care. 2007;11:411. [PMC free article] [PubMed]
14. Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U, Eckardt KU, Loeffler M, John S. Acute renal failure in patients with severe sepsis and septic shock--a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant. 2008;23:904–909. [PubMed]
15. Yegenaga I, Hoste E, Van Biesen W, Vanholder R, Benoit D, Kantarci G, Dhondt A, Colardyn F, Lameire N. Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. Am J Kidney Dis. 2004;43:817–824. [PubMed]
16. Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol. 2003;14:1022–1030. [PubMed]
17. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–1310. [PubMed]
18. Moore LJ, Moore FA, Todd SR, Jones SL, Turner KL, Bass BL. Sepsis in general surgery: the 2005 2007 national surgical quality improvement program perspective. Arch Surg. 2010;145:695–700. [PubMed]
19. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–1655. [PubMed]
20. Moore LJ, Moore FA, Jones SL, Xu J, Bass BL. Sepsis in general surgery: a deadly complication. Am J Surg. 2009;198:868–874. [PubMed]
21. Moore L, Turner K, Todd S, Sucher J, Mckinley B, Moore F. Computerized clinical decision support improves mortality in intra abdominal surgical sepsis. American Journal of Surgery. 2010 [PubMed]
22. Decker D, Tolba R, Springer W, Lauschke H, Hirner A, von Ruecker A. Abdominal surgical interventions: local and systemic consequences for the immune system--a prospective study on elective gastrointestinal surgery. J Surg Res. 2005;126:12–18. [PubMed]
23. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O’Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010;11:79–109. [PubMed]
24. Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med. 1983;107:543–547. [PubMed]
25. Molitoris BA. Renal blood flow in sepsis: a complex issue. Crit Care. 2005;9:327–328. [PMC free article] [PubMed]
26. Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S. Renal blood flow in sepsis. Crit Care. 2005;9:R363–374. [PMC free article] [PubMed]
27. Bellomo R, Wan L, Langenberg C, May C. Septic acute kidney injury: new concepts. Nephron Exp Nephrol. 2008;109:e95–100. [PubMed]
28. Wan L, Langenberg C, Bellomo R, May CN. Angiotensin II in experimental hyperdynamic sepsis. Crit Care. 2009;13:R190. [PMC free article] [PubMed]
29. Lerolle N, Nochy D, Guerot E, Bruneval P, Fagon JY, Diehl JL, Hill G. Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. Intensive Care Med. 2010;36:471–478. [PubMed]
30. Baud L, Oudinet JP, Bens M, Noe L, Peraldi MN, Rondeau E, Etienne J, Ardaillou R. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int. 1989;35:1111–1118. [PubMed]
31. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol. 2002;168:5817–5823. [PubMed]
32. Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, Gengaro PE, Esson M, Edelstein CL, Dinarello CA, Schrier RW. Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int. 2001;59:2243–2249. [PubMed]
33. Jo SK, Cha DR, Cho WY, Kim HK, Chang KH, Yun SY, Won NH. Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells. Nephron. 2002;91:406–415. [PubMed]
34. Schumer M, Colombel MC, Sawczuk IS, Gobe G, Connor J, O’Toole KM, Olsson CA, Wise GJ, Buttyan R. Morphologic, biochemical, and molecular evidence of apoptosis during the reperfusion phase after brief periods of renal ischemia. Am J Pathol. 1992;140:831–838. [PubMed]
35. Guo R, Wang Y, Minto AW, Quigg RJ, Cunningham PN. Acute renal failure in endotoxemia is dependent on caspase activation. J Am Soc Nephrol. 2004;15:3093–3102. [PubMed]
36. Zhang X, Zheng X, Sun H, Feng B, Chen G, Vladau C, Li M, Chen D, Suzuki M, Min L, Liu W, Garcia B, Zhong R, Min WP. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation. 2006;82:1728–1732. [PubMed]
37. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ., Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. [PubMed]
38. Schetz M, Vanhorebeek I, Wouters PJ, Wilmer A, Van den Berghe G. Tight blood glucose control is renoprotective in critically ill patients. J Am Soc Nephrol. 2008;19:571–578. [PubMed]
39. Mesotten D, Swinnen JV, Vanderhoydonc F, Wouters PJ, Van den Berghe G. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab. 2004;89:219–226. [PubMed]
40. Thiemermann C, Patel NS, Kvale EO, Cockerill GW, Brown PA, Stewart KN, Cuzzocrea S, Britti D, Mota-Filipe H, Chatterjee PK. High density lipoprotein (HDL) reduces renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003;14:1833–1843. [PubMed]
41. Zager RA, Johnson AC, Hanson SY. Renal tubular triglyercide accumulation following endotoxic, toxic, and ischemic injury. Kidney Int. 2005;67:111–121. [PubMed]
42. Melin J, Hellberg O, Larsson E, Zezina L, Fellstrom BC. Protective effect of insulin on ischemic renal injury in diabetes mellitus. Kidney Int. 2002;61:1383–1392. [PubMed]
43. Mehta RL. Glycemic control and critical illness: is the kidney involved? J Am Soc Nephrol. 2007;18:2623–2627. [PubMed]
44. Gupta A, Berg DT, Gerlitz B, Sharma GR, Syed S, Richardson MA, Sandusky G, Heuer JG, Galbreath EJ, Grinnell BW. Role of protein C in renal dysfunction after polymicrobial sepsis. J Am Soc Nephrol. 2007;18:860–867. [PubMed]
45. Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: why drugs haven’t worked and what is on the horizon. Clin J Am Soc Nephrol. 2007;2:356–365. [PubMed]
46. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004;66:1613–1621. [PubMed]
47. Xue JL, D. F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J, Collins AJ. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol. 2006;17:1135–1142. [PubMed]
48. Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003;14:1549–1558. [PubMed]
49. Kramer AA, Postler G, Salhab KF, Mendez C, Carey LC, Rabb H. Renal ischemia/reperfusion leads to macrophage-mediated increase in pulmonary vascular permeability. Kidney Int. 1999;55:2362–2367. [PubMed]
50. Rabb H, Wang Z, Postler G, Soleimani M. Possible molecular basis for changes in potassium handling in acute renal failure. Am J Kidney Dis. 2000;35:871–877. [PubMed]
51. Zarbock A, Schmolke M, Spieker T, Jurk K, Van Aken H, Singbartl K. Acute uremia but not renal inflammation attenuates aseptic acute lung injury: a critical role for uremic neutrophils. J Am Soc Nephrol. 2006;17:3124–3131. [PubMed]
52. Hassoun HT, Grigoryev DN, Lie ML, Liu M, Cheadle C, Tuder RM, Rabb H. Ischemic acute kidney injury induces a distant organ functional and genomic response distinguishable from bilateral nephrectomy. Am J Physiol Renal Physiol. 2007;293:F30–40. [PubMed]
53. Hoke TS, Douglas IS, Klein CL, He Z, Fang W, Thurman JM, Tao Y, Dursun B, Voelkel NF, Edelstein CL, Faubel S. Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J Am Soc Nephrol. 2007;18:155–164. [PubMed]
54. Doi K, Leelahavanichkul A, Yuen PS, Star RA. Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest. 2009;119:2868–2878. [PMC free article] [PubMed]
55. Ricci Z, Ronco C. Pulmonary/renal interaction. Curr Opin Crit Care. 2010;16:13–18. [PubMed]
56. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818–824. [PubMed]
57. Groeneveld AB, Tran DD, van der Meulen J, Nauta JJ, Thijs LG. Acute renal failure in the medical intensive care unit: predisposing, complicating factors and outcome. Nephron. 1991;59:602–610. [PubMed]
58. Rabb H, Chamoun F, Hotchkiss J. Molecular mechanisms underlying combined kidney-lung dysfunction during acute renal failure. Contrib Nephrol. 2001:41–52. [PubMed]
59. Rabb H, Wang Z, Nemoto T, Hotchkiss J, Yokota N, Soleimani M. Acute renal failure leads to dysregulation of lung salt and water channels. Kidney Int. 2003;63:600–606. [PubMed]
60. Mehta RL, Pascual MT, Gruta CG, Zhuang S, Chertow GM. Refining predictive models in critically ill patients with acute renal failure. J Am Soc Nephrol. 2002;13:1350–1357. [PubMed]
61. Klein CL, Hoke TS, Fang WF, Altmann CJ, Douglas IS, Faubel S. Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney Int. 2008;74:901–909. [PubMed]
62. Lemay S, Rabb H, Postler G, Singh AK. Prominent and sustained up-regulation of gp130-signaling cytokines and the chemokine MIP-2 in murine renal ischemia-reperfusion injury. Transplantation. 2000;69:959–963. [PubMed]
63. Grigoryev DN, Liu M, Hassoun HT, Cheadle C, Barnes KC, Rabb H. The local and systemic inflammatory transcriptome after acute kidney injury. J Am Soc Nephrol. 2008;19:547–558. [PubMed]
64. Feltes CM, Van Eyk J, Rabb H. Distant-organ changes after acute kidney injury. Nephron Physiol. 2008;109:p80–84. [PubMed]
65. Fine A, Janssen-Heininger Y, Soultanakis RP, Swisher SG, Uhal BD. Apoptosis in lung pathophysiology. Am J Physiol Lung Cell Mol Physiol. 2000;279:L423–427. [PubMed]
66. Matute-Bello G, Liles WC, Radella F, 2nd, Steinberg KP, Ruzinski JT, Jonas M, Chi EY, Hudson LD, Martin TR. Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;156:1969–1977. [PubMed]
67. Matute-Bello G, Liles WC, Steinberg KP, Kiener PA, Mongovin S, Chi EY, Jonas M, Martin TR. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS) J Immunol. 1999;163:2217–2225. [PubMed]
68. Rafi AQ, Zeytun A, Bradley MJ, Sponenberg DP, Grayson RL, Nagarkatti M, Nagarkatti PS. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome. J Immunol. 1998;161:3077–3086. [PubMed]
69. Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol. 2001;91:1487–1500. [PubMed]
70. Hassoun HT, Lie ML, Grigoryev DN, Liu M, Tuder RM, Rabb H. Kidney ischemia-reperfusion injury induces caspase-dependent pulmonary apoptosis. Am J Physiol Renal Physiol. 2009;297:F125–137. [PubMed]
71. Jang HR, Ko GJ, Wasowska BA, Rabb H. The interaction between ischemia-reperfusion and immune responses in the kidney. J Mol Med. 2009;87:859–864. [PubMed]
72. Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, O’Donnell MP, Rabb H. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest. 2001;108:1283–1290. [PMC free article] [PubMed]
73. Wang S, Diao H, Guan Q, Cruikshank WW, Delovitch TL, Jevnikar AM, Du C. Decreased renal ischemia-reperfusion injury by IL-16 inactivation. Kidney Int. 2008;73:318–326. [PubMed]
74. Burne-Taney MJ, Liu M, Ascon D, Molls RR, Racusen L, Rabb H. Transfer of lymphocytes from mice with renal ischemia can induce albuminuria in naive mice: a possible mechanism linking early injury and progressive renal disease? Am J Physiol Renal Physiol. 2006;291:F981–986. [PubMed]
75. Liu M, Chien CC, Grigoryev DN, Gandolfo MT, Colvin RB, Rabb H. Effect of T cells on vascular permeability in early ischemic acute kidney injury in mice. Microvasc Res. 2009;77:340–347. [PubMed]
76. Kim do J, Park SH, Sheen MR, Jeon US, Kim SW, Koh ES, Woo SK. Comparison of experimental lung injury from acute renal failure with injury due to sepsis. Respiration. 2006;73:815–824. [PubMed]
77. Tokuyama H, Kelly DJ, Zhang Y, Gow RM, Gilbert RE. Macrophage infiltration and cellular proliferation in the non-ischemic kidney and heart following prolonged unilateral renal ischemia. Nephron Physiol. 2007;106:p54–62. [PubMed]
78. Lie ML, L. M, Grigoryev DN, Rabb H, Hassoun HT. Academic Surgical Congress. Fort Meyers, FL: 2009. Cytotoxic T cell mediated distant organ dysfunction during ischemic acute kidney injury.
79. Li X, Hassoun HT, Santora R, Rabb H. Organ crosstalk: the role of the kidney. Curr Opin Crit Care. 2009;15:481–487. [PubMed]
80. Blake P, Hasegawa Y, Khosla MC, Fouad-Tarazi F, Sakura N, Paganini EP. Isolation of “myocardial depressant factor(s)” from the ultrafiltrate of heart failure patients with acute renal failure. Asaio J. 1996;42:M911–915. [PubMed]
81. Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol. 2006;17:1143–1150. [PubMed]
82. Kuhar C. Grasic, Budihna MV, Pleskovic RZ. Mibefradil is more effective than verapamil for restoring post-ischemic function of isolated hearts of guinea pigs with acute renal failure. Eur J Pharmacol. 2004;488:137–146. [PubMed]
83. Langenberg C, Bellomo R, May CN, Egi M, Wan L, Morgera S. Renal vascular resistance in sepsis. Nephron Physiol. 2006;104:p1–11. [PubMed]
84. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 1998;97:1375–1381. [PubMed]
85. Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg. 2004;107:1–16. [PubMed]
86. Liu M, Liang Y, Chigurupati S, Lathia JD, Pletnikov M, Sun Z, Crow M, Ross CA, Mattson MP, Rabb H. Acute kidney injury leads to inflammation and functional changes in the brain. J Am Soc Nephrol. 2008;19:1360–1370. [PMC free article] [PubMed]
87. Masumoto T, Ohkubo K, Yamamoto K, Ninomiya T, Abe M, Akbar SM, Michitaka K, Horiike N, Onji M. Serum IL-8 levels and localization of IL-8 in liver from patients with chronic viral hepatitis. Hepatogastroenterology. 1998;45:1630–1634. [PubMed]
88. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol. 2001;166:6812–6819. [PubMed]
89. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003;37:1043–1055. [PubMed]
90. Golab F, Kadkhodaee M, Zahmatkesh M, Hedayati M, Arab H, Schuster R, Zahedi K, Lentsch AB, Soleimani M. Ischemic and non-ischemic acute kidney injury cause hepatic damage. Kidney Int. 2009;75:783–792. [PubMed]
91. Cornu-Labat G, Serra M, Smith A, McGregor WE, Kasirajan K, Hirko MK, Turner JJ, Rubin JR. Systemic consequences of oxidative stress following aortic surgery correlate with the degree of antioxidant defenses. Ann Vasc Surg. 2000;14:31–36. [PubMed]
92. Misthos P, Katsaragakis S, Theodorou D, Milingos N, Skottis I. The degree of oxidative stress is associated with major adverse effects after lung resection: a prospective study. Eur J Cardiothorac Surg. 2006;29:591–595. [PubMed]
93. Ruzic B, Tomaskovic I, Trnski D, Kraus O, Bekavac-Beslin M, Vrkic N. Systemic stress responses in patients undergoing surgery for benign prostatic hyperplasia. BJU Int. 2005;95:77–80. [PubMed]
94. Leelahavanichkul A, Yasuda H, Doi K, Hu X, Zhou H, Yuen PS, Star RA. Methyl-2-acetamidoacrylate, an ethyl pyruvate analog, decreases sepsis-induced acute kidney injury in mice. Am J Physiol Renal Physiol. 2008;295:F1825–1835. [PubMed]
95. Sappington PL, Cruz RJ, Jr., Harada T, Yang R, Han Y, Englert JA, Ajami AA, Killeen ME, Delude RL, Fink MP. The ethyl pyruvate analogues, diethyl oxaloproprionate, 2-acetamidoacrylate, and methyl-2-acetamidoacrylate, exhibit anti-inflammatory properties in vivo and/or in vitro. Biochem Pharmacol. 2005;70:1579–1592. [PubMed]
96. Carrico CJ, Meakins JL, Marshall JC, Fry D, Maier RV. Multiple-organ-failure syndrome. Arch Surg. 1986;121:196–208. [PubMed]
97. Clark JA, Coopersmith CM. Intestinal crosstalk: a new paradigm for understanding the gut as the “motor” of critical illness. Shock. 2007;28:384–393. [PMC free article] [PubMed]
98. Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA. Post-injury multiple organ failure: the role of the gut. Shock. 2001;15:1–10. [PubMed]
99. Fink MP, Delude RL. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care Clin. 2005;21:177–196. [PubMed]
100. Alverdy JC, Laughlin RS, Wu L. Influence of the critically ill state on host-pathogen interactions within the intestine: gut-derived sepsis redefined. Crit Care Med. 2003;31:598–607. [PubMed]
101. Senthil M, Brown M, Xu DZ, Lu Q, Feketeova E, Deitch EA. Gut-lymph hypothesis of systemic inflammatory response syndrome/multiple-organ dysfunction syndrome: validating studies in a porcine model. J Trauma. 2006;60:958–965. discussion 965-957. [PubMed]
102. Hayes CP, Jr., McLeod ME, Robinson RR. An extravenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Physicians. 1967;80:207–216. [PubMed]
103. Martin RS, Panese S, Virginillo M, Gimenez M, Litardo M, Arrizurieta E, Hayslett JP. Increased secretion of potassium in the rectum of humans with chronic renal failure. Am J Kidney Dis. 1986;8:105–110. [PubMed]
104. Gimelreich D, Popovtzer MM, Wald H, Pizov G, Berlatzky Y, Rubinger D. Regulation of ROMK and channel-inducing factor (CHIF) in acute renal failure due to ischemic reperfusion injury. Kidney Int. 2001;59:1812–1820. [PubMed]